Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty

作者: James J. Ferguson , Kathryn G. Dougherty , Carlos M. Gaos , Howard S. Bush , Kathryn C. Marsh

DOI: 10.1016/0735-1097(94)90590-8

关键词:

摘要: Objectives. The purpose of this study was to determine whether a low procedural activated coagulation time is associated with high rate in-hospital complications and identify there an range that may be complications. Background. In recent years the has come into widespread use for monitoring anticoagulation in catheterization laboratory. However, considerable controversy exists as standards by which judge “adequate” interventional procedures. Methods. From total 1,469 consecutive patients percutaneous transluminal coronary angioplasty, we retrospectively identified 103 (Group I, 7% overall population) major death or emergency urgent artery bypass graft surgery compared them 400 without II). Group I had more risk clinical characteristics, such type B C lesions, class III IV angina, myocardial infarction thrombolytic treatment. Activated times were between Groups II at baseline, after administration 10,000 U heparin end procedure. Results. There no differences baseline II. significantly lower therapy procedure: 61% 300 s; 279 27% s (p s. Conclusions. A diminished response initial bolus although did have higher before procedure. It remains determined ideal “target” procedures.

参考文章(15)
Brian S. Bull, Ralph A. Korpman, Wilfred M. Huse, Bernard D. Briggs, Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 69, pp. 674- 684 ,(1975) , 10.1016/S0022-5223(19)41499-2
James J. Ferguson, All ACTs are not created equal. Texas Heart Institute Journal. ,vol. 19, pp. 1- 3 ,(1992)
Brian S. Bull, Wilfred M. Huse, Floyd S. Brauer, Ralph A. Korpman, Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 69, pp. 685- 689 ,(1975) , 10.1016/S0022-5223(19)41500-6
Paul G. Hattersley, Activated Coagulation Time of Whole Blood JAMA: The Journal of the American Medical Association. ,vol. 196, pp. 436- 440 ,(1966) , 10.1001/JAMA.1966.03100180108036
Kenneth L. Mattox, Gene A. Guinn, Pedro A. Rubio, Arthur C. Beall, Use of the Activated Coagulation Time in Intraoperative Heparin Reversal for Cardiopulmonary Operations The Annals of Thoracic Surgery. ,vol. 19, pp. 634- 638 ,(1975) , 10.1016/S0003-4975(10)63823-4
J. Donald Hill, Leon Dontigny, Marc de Leval, C. Harold Mielke, A Simple Method of Heparin Management During Prolonged Extracorporeal Circulation The Annals of Thoracic Surgery. ,vol. 17, pp. 129- 134 ,(1974) , 10.1016/S0003-4975(10)65621-4
J. David Ogilby, Harry A. Kopelman, Lloyd W. Klein, Jai B. Agarwal, Adequate heparinization during PTCA: assessment using activated clotting times. Catheterization and Cardiovascular Diagnosis. ,vol. 18, pp. 206- 209 ,(1989) , 10.1002/CCD.1810180403
John A Young, C Thomas Kisker, Donald B Doty, None, Adequate Anticoagulation During Cardiopulmonary Bypass Determined by Activated Clotting Time and the Appearance of Fibrin Monomer The Annals of Thoracic Surgery. ,vol. 26, pp. 231- 240 ,(1978) , 10.1016/S0003-4975(10)63676-4